Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood–Brain Barrier: The Discovery of AZD1390-Reference-Cited by-全球学者库

Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood–Brain Barrier: The Discovery of AZD1390

Published:2024-02-02 Issue: Volume: Page:
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pike Kurt G.¹^ORCID,Hunt Thomas A.¹^ORCID,Barlaam Bernard¹^ORCID,Benstead David²,Cadogan Elaine¹,Chen Kan³,Cook Calum R.²,Colclough Nicola¹,Deng Chao⁴,Durant Stephen T.¹,Eatherton Andrew¹,Goldberg Kristin¹,Johnström Peter⁵⁶,Liu Libin⁴,Liu Zhaoqun⁴,Nissink J. Willem M.¹,Pang Chengling⁴,Pass Martin¹,Robb Graeme R.¹^ORCID,Roberts Caroline⁷,Schou Magnus⁵⁶^ORCID,Steward Oliver¹,Sykes Andy¹,Yan Yumei³,Zhai Baochang⁴,Zheng Li³

Affiliation:

1. Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

2. Pharmaceutical Sciences, AstraZeneca, Silk Road Business Park, Macclesfield SK10 2NA, U.K.

3. Innovation Center China, Asia & Emerging Markets iMED, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China

4. Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China

5. PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden

6. Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden

7. Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02277

Reference64 articles.

1. Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions

2. Current and Investigational Drug Strategies for Glioblastoma

3. Crossing the blood–brain barrier: are we getting it right?

4. Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma

5. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data